Perceptions of prognosis in patients with advanced lung cancer: Associations with patient demographics, quality of life, and depression symptoms.

Authors

null

Jacqueline Han

Massachusetts General Hospital, Boston, MA

Jacqueline Han, Kathryn Elizabeth Post, Emily R Gallagher-Medeiros, Chardria Trotter, Lauren Heuer, Rachel Plotke, Yael Turk, Simone Rinaldi, Mihir Kamdar, Vicki A. Jackson, Elyse R. Park, Areej El-Jawahri, Jennifer S. Temel, Joseph A. Greer

Organizations

Massachusetts General Hospital, Boston, MA, Department of Psychiatry and Medicine, Massachusetts General Hospital, Boston, MA, Division of Hematology & Oncology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health, Patient-Centered Outcomes Research Institute.

Background: Despite the importance of having a clear understanding of the likely outcome of cancer to inform medical decision-making, about one third of patients with advanced lung cancer report inaccurate perceptions of their prognosis. To identify factors associated with lower and higher prognostic understanding, we examined the relationships among patients’ perceptions of prognosis and their demographic characteristics, quality of life (QOL), and mood symptoms. Methods: We conducted a cross-sectional analysis of baseline data from patients enrolled in two multisite palliative care trials. Eligible participants included adults with advanced non-small cell lung cancer, small cell lung cancer, or mesothelioma diagnosed in the past 12 weeks and an ECOG Performance Status <3 across 23 cancer centers in the US. At baseline, patients self-reported their current health status and understanding of whether their cancer is curable. Patients’ prognostic understanding was categorized into three levels: “high” if patients reported that their illness was terminal and incurable, “medium” if patients reported that their illness was either terminal or incurable, and “low” if patients reported that their illness was neither terminal nor incurable. To assess QOL and depression symptoms, patients completed the Functional Assessment of Cancer Therapy-Lung (FACT-L) and the Patient Health Questionnaire-9 (PHQ-9), respectively. Linear regression models adjusting for patient demographic factors were used to examine the associations among prognostic understanding, QOL, and depression symptoms. Results: The sample included 1430 patients with advanced lung cancer (Mean age = 65.50 years; 52.5% female; 4.0% Asian, 10.6% Black, 81.8% White; 65.9% married). Patient-reported prognostic understanding varied as follows: high (45.1%), medium (32.7%), and low (22.2%). Patients who were older (p =.015), male (p <.001), Black or Asian (p =.015), or married (p =.012) had lower prognostic understanding. Adjusting for demographic factors, patients with higher prognostic understanding reported worse QOL (FACT-L: B = -5.392, SE = 0.71, p <.001) and depression symptoms (PHQ-9: B = 0.99, SE = 0.19, p < 0.001) versus those with lower prognostic understanding. Conclusions: A substantial proportion of patients with newly diagnosed advanced lung cancer have low prognostic understanding. Those with high prognostic understanding report worse QOL and depression symptoms, which may be due to patients relating their poor health status to their prognosis. Furthermore, patient age, gender, race, and relationship status are salient correlates of prognostic understanding. Tailored interventions are needed to improve illness understanding and address the related supportive care needs of patients with advanced lung cancer, especially those at risk for low prognostic understanding.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience

Sub Track

Communication and Shared Decision-Making Research

Citation

J Clin Oncol 40, 2022 (suppl 28; abstr 247)

DOI

10.1200/JCO.2022.40.28_suppl.247

Abstract #

247

Poster Bd #

F16

Abstract Disclosures